Trial Profile
A Phase II Study of Crenolanib Besylate Maintenance Following Allogeneic Stem Cell Transplantation in Patients With FLT3-positive Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 28 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology